KLOW blend

KLOW is a four-peptide research blend combining GHK-Cu, BPC-157, TB-500, and KPV in one lyophilised vial, sold strictly for research use only. The lab test table and shop directory above show Peptigrity's independent verification data for KLOW vials — whole-vial HPLC purity plus per-component net content — updated as new certificates are submitted.

What is KLOW and what's actually in the vial?

KLOW is a four-peptide research blend combining GHK-Cu, BPC-157, TB-500 (labelled on most certificates as Thymosin Beta-4), and KPV in a single lyophilised vial, most commonly at 80 mg total in a 50:10:10:10 ratio. It is the three-peptide GLOW blend plus KPV — the "K." Each component is a distinct compound with its own mechanism: the blend targets overlapping tissue-repair and anti-inflammatory pathways rather than a single receptor. KLOW is not an approved drug in any jurisdiction.

The four components, and what each contributes:

The copper in GHK-Cu gives a correctly-made KLOW vial a distinctive pale-blue tint — a labelled "Blue Lyophilized Powder" on a certificate is consistent with GHK-Cu being present, though it is a visual cue, not a purity guarantee.

What does the research show for KLOW's four peptides?

…as of August 2026 — every efficacy claim about the combination is extrapolated from single-compound research, most of it preclinical. The four components differ sharply in how much evidence stands behind them, so they should not be treated as equally proven.

GHK-Cu has the broadest human-relevant record, largely from the foundational copper-peptide work of Dr. Loren Pickart, with documented effects on collagen and wound-repair gene expression — much of it in dermatological and in vitro contexts (evidence level: preclinical and cosmetic-human). BPC-157 is supported by more than 100 preclinical studies, predominantly from Prof. Predrag Sikirić's group at the University of Zagreb, beginning with the 1993 foundational paper; a 2025 orthopaedic systematic review found only one clinical study met inclusion criteria among 544 screened, underscoring that human data remains minimal (evidence level: preclinical; no human RCTs). TB-500 itself has preclinical wound-healing data only — the one first-in-human Phase 1 safety trial in this family tested recombinant thymosin β4, the full parent protein, not the TB-500 fragment; no human trial of TB-500 has been published (evidence level: preclinical; parent-protein Phase 1 safety only). KPV has preclinical anti-inflammatory data — significant effects in murine colitis models, mediated by dampened NF-κB signalling — and no human trials (evidence level: preclinical only).

The component-level science is covered in depth in the GHK-Cu science guide, the BPC-157 science guide, and the TB-500 science guide.

How does KLOW compare to GLOW?

KLOW is GLOW with one added component: GLOW is a three-peptide blend (GHK-Cu, BPC-157, TB-500); KLOW adds KPV for a fourth. GLOW is oriented toward tissue repair and skin, while KLOW layers in KPV's anti-inflammatory signalling. GLOW's composition varies widely between shops (from roughly 10 mg to 70 mg total), whereas KLOW is more standardised around 80 mg at 50:10:10:10. Neither blend has controlled human trial data; both inherit their rationale from single-compound research.

For the two-peptide repair pairing many buyers compare against, see BPC-157 vs TB-500.

Why is a blend like KLOW harder to verify than a single peptide?

A blend is harder to verify because a single purity figure cannot tell you whether all four peptides are present in the right amounts. A certificate reports a whole-vial HPLC purity (how clean the material is, e.g. 99.62%) — but that number can read above 99% while one component is substantially underdosed. The verifiable questions for a blend are therefore per-component: identity (is each peptide actually in the vial, confirmed by mass spectrometry) and net content (does each component's tested milligram amount match the label). This is exactly where a blend can fail quietly — a vial can be clean, correctly labelled overall, and still short one expensive component. Peptigrity's independent lab-test database tracks both dimensions; for how to read these results yourself, see how to read peptide lab test results.

How does Peptigrity verify a KLOW vial?

Peptigrity verifies a KLOW vial through four independent measurements from an accredited third-party lab: LC-MS identity confirming each of the four peptides is present, HPLC-UV purity for the whole vial, per-component net content (tested mg versus labelled mg for GHK-Cu, BPC-157, TB-500, and KPV individually), and endotoxin testing. On a representative certificate from Freedom Diagnostics, a KLOW vial returned 99.62% HPLC purity with all four identities confirmed — but net content showed GHK-Cu measured at roughly 57 mg against a 50 mg label, the kind of per-component variance a single purity number would conceal. Peptigrity purchases vials anonymously at standard pricing and publishes the unedited certificate; the methodology, including the trust-score weighting applied to shops, is documented in how we calculate trust scores. The wider verification process is covered in the how to test peptides hub and the testing labs directory.

How do you dose a multi-peptide blend like KLOW?

In a fixed blend you can only set the dose of one component — the ratio then determines the other three, which is what makes blend dosing different from single-peptide dosing. If you reconstitute an 80 mg KLOW vial and dose to a target amount of BPC-157, the GHK-Cu, TB-500, and KPV amounts are locked by the 50:10:10:10 ratio and cannot be adjusted independently. The blend calculator works this math per component so the peptide you care about isn't accidentally underdosed. No clinical dosing protocol exists for KLOW; any figure is community-derived from single-compound research, not a validated regimen. For component-level dosing context, see the GHK-Cu dosage guide and the BPC-157 + TB-500 stack guide.

What is the regulatory status of KLOW's components?

…as of August 2026, and KLOW is sold strictly as a research-use-only compound. In April 2026 the FDA removed BPC-157, TB-500, and KPV from its 503A Category 2 bulk-substances list because the nominations had been withdrawn by the nominators — an administrative removal that did not add them to Category 1 or authorise pharmacy compounding. They remain in a regulatory gray zone: no FDA-approved product, no USP monograph, neither cleared for nor formally barred from compounding. At its July 23–24, 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, and TB-500 (each 8–6–1) for the 503A compounding list — recommendations the FDA's own reviewers had opposed in their pre-meeting briefing. These votes are advisory only; the FDA has not finalized them, and formal rulemaking is not expected before 2027. Injectable GHK-Cu sits on a separate track — slated for a distinct PCAC consultation before the end of February 2027. BPC-157 and TB-500 are both prohibited by the World Anti-Doping Agency (BPC-157 under S0; TB-500/thymosin β4 under S2.3, Growth Factors), so any blend containing them is banned in sport. Buyers are responsible for confirming local import rules for research chemicals in their jurisdiction.